Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ikena Oncology (NASDAQ:IKNA) in a report published on Monday morning,Benzinga reports. They currently have a $4.00 target price on the stock. HC Wainwright also issued estimates for Ikena Oncology’s Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($0.95) EPS, Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($0.70) EPS.

Separately, Wedbush reissued a “neutral” rating and set a $2.00 price objective on shares of Ikena Oncology in a report on Thursday, November 7th.

Ikena Oncology Trading Down 1.7 %

NASDAQ:IKNA opened at $1.71 on Monday. The stock has a market capitalization of $82.52 million, a P/E ratio of -1.41 and a beta of 0.48. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $2.32. The firm has a 50 day moving average of $1.71 and a 200-day moving average of $1.65.

Ikena Oncology (NASDAQ:IKNA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.08. As a group, analysts forecast that Ikena Oncology will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Ikena Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Ikena Oncology during the second quarter valued at $30,000. FMR LLC boosted its stake in shares of Ikena Oncology by 94.1% in the 3rd quarter. FMR LLC now owns 38,374 shares of the company’s stock valued at $66,000 after purchasing an additional 18,607 shares during the last quarter. BBR Partners LLC bought a new position in shares of Ikena Oncology in the 2nd quarter valued at about $33,000. AQR Capital Management LLC acquired a new stake in shares of Ikena Oncology during the 2nd quarter worth approximately $36,000. Finally, NEA Management Company LLC raised its stake in shares of Ikena Oncology by 5.3% during the third quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock worth $1,038,000 after buying an additional 30,013 shares during the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

About Ikena Oncology

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.